Department of Surgery, Charles University, University Hospital Pilsen, Pilsen, Czech Republic
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Anticancer Res. 2019 Nov;39(11):6063-6066. doi: 10.21873/anticanres.13813.
BACKGROUND/AIM: Treatment of colorectal cancer (CRC) does not reflect immune interactions between tumours and macro-organisms. Serpin B9 is known as an inhibitor of Granzyme B. The aim of this study was to evaluate the impact of the expression of Serpin B9 in CRC and healthy colon tissue on prognosis.
This retrospective study included 74 CRC patients in all stages. Analysis of gene expression was performed with quantitative polymerase chain reaction with reverse transcription using specific primers and master mix Xceed qPCR SG. Expression was normalized to the reference genes GAPDH, ACTB, and PSMC.
Increased expression of Serpin B9 in healthy tissue was significantly associated with longer overall survival (OS). This association was found both in all patients and in the group of patients with distant metastases.
The presented results support previous evidence of positive influence of the interaction between immune system and tumour on the prognosis of CRC.
背景/目的：结直肠癌（CRC）的治疗并未反映肿瘤与大器官之间的免疫相互作用。丝氨酸蛋白酶抑制剂 B9 已知是 Granzyme B 的抑制剂。本研究的目的是评估 CRC 和健康结肠组织中 Serpin B9 的表达对预后的影响。
本回顾性研究共纳入 74 例各期 CRC 患者。使用特异性引物和 mastermix Xceed qPCR SG 通过逆转录定量聚合酶链反应进行基因表达分析。表达以 GAPDH、ACTB 和 PSMC 这 3 个参考基因进行标准化。
健康组织中 Serpin B9 的高表达与总生存期（OS）延长显著相关。这种相关性在所有患者和远处转移患者组中均存在。
本研究结果支持免疫系统与肿瘤之间相互作用对 CRC 预后有积极影响的先前证据。
